Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOMINATE-2: Non-operative Management after Chemoradiotherapy plus Sandwich mFOLFOXIRI in Locally Advanced Rectal Cancer
jRCTs051250182Phase 2Recruiting
- Start
- Jan 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, irinotecan, fluorouracil, folinic acid and capecitabine in rectal cancer. Primary endpoint: Primary: Proportion of patients achieving cCR or near-cCR and undergoing non-operative management. Started Jan 2026; status: recruiting.
02
Drugs
oxaliplatinirinotecanfluorouracilfolinic acidcapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on jRCTs051250182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051250182.